Kura Oncology, Inc.
(NASDAQ : KURA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.17%358.711.2%$830.53m
AMGNAmgen Inc.
-0.66%190.491.2%$543.11m
CELGCelgene Corporation
-0.28%85.101.2%$507.54m
GILDGilead Sciences, Inc.
0.42%77.370.9%$473.45m
VRTXVertex Pharmaceuticals Incorporated
-1.51%177.401.9%$313.54m
REGNRegeneron Pharmaceuticals, Inc.
-0.17%367.112.6%$276.88m
ILMNIllumina, Inc.
0.66%311.153.5%$269.38m
BLUEBluebird Bio, Inc.
0.78%180.3515.7%$197.52m
SRPTSarepta Therapeutics, Inc.
-1.64%133.3116.6%$196.81m
ALXNAlexion Pharmaceuticals, Inc.
0.05%135.162.0%$178.57m
NKTRNektar Therapeutics
-0.71%48.735.6%$172.03m
EXASExact Sciences Corporation
0.02%67.6225.4%$155.70m
EXELExelixis, Inc.
-0.23%21.296.4%$135.36m
BMRNBioMarin Pharmaceutical Inc.
-0.94%101.904.4%$122.64m
AAgilent Technologies, Inc.
-0.45%63.861.5%$110.57m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.